Cancer-induced, immune-mediated ocular degenerations

Ocular Immunology and Inflammation

Volumn 13, Issue 2-3, 2005, Pages 119-131

  Thirkill, Charles E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer induced autoimmunity; Optic neuritis; Retinopathy

Indexed keywords

AUTOANTIGEN; RECOVERIN; RETINA ANTIGEN;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLINDNESS; CANCER GROWTH; CELL PROLIFERATION; EYE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MELANOMA; NONHUMAN; OPTIC NERVE DISEASE; PARANEOPLASTIC SYNDROME; RETINA DEGENERATION; RETINOPATHY; REVIEW; SENSITIZATION; ANIMAL; DISEASE COURSE; IMMUNOLOGY; OPTIC NEURITIS; RISK FACTOR;

ANIMALS; AUTOIMMUNITY; DISEASE PROGRESSION; HUMANS; OPTIC NEURITIS; PARANEOPLASTIC SYNDROMES; RETINAL DEGENERATION; RISK FACTORS;

EID: 25144473205     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940590928733     Document Type: Review

References (218)

1. Budde-Steffen C, Andersen NE, Rosenblum MK, et al. An antineuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol. 1988;23:528-531.
2. Budde-Steffen C, Anderson NE, Rosenblum MK, Posner JB. Expression of an antigen in small cell lung carcinoma lines detected by antibodies from patients with paraneoplastic dorsal root ganglionpathy. Cancer Res. 1988;48:430-434.
3. Gazdar AF, Carbone DR The biology and molecular genetics of lung cancer. Austin/Georgetown: R.G. Landes Company, CRC Press, 1994.
4. Thirkill CE. Retinal autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo: Elsevier, 1997;694-699.
5. Hildebrand J. Paraneoplastic syndromes. II. Neurological paraneoplasia. Eur J Cancer Clin Oncol. 1981;17(9):985-990 (Review).
6. Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2- deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124(Pt 11):2223-2231.
7. Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri). Neurology. 1994;44:2241-2246.
8. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical ana lysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42:1931-1937.
9. Thirkill CE. Immunology of paraneoplastic syndromes. In: Zierhut M, Jager M, Ksander B, editors. Immunology of ocular tumors. Lisse; The Netherlands: Aeolus Press/Swets & Zeitlinger, 2002;237-254.
10. Ottinetti A, Colombo E, Dardano F, et al. Cutaneous metastasis of neuroendocrine carcinoma of the larynx: report of a case. J Cutan Pathol. 2003;30(8):512-515.
11. Weed Jr JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg. 2003;197(1):44-51.
12. Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract Am J Clin Pathol. 2001;115(Suppl):S94-112 (Review).
13. Posner JB, Dalmau JO. Yet another paraneoplastic antibody. Ann Neurol. 2002;49(2):141-142.
14. Posner JB, Dalmau JO. Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med. 2000;38(2):117-122 (Review).
15. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms; immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481-1494.
16. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol. 1983;101:564-569.
17. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol. 1987;105:372-375.
18. Thirkill CE, FitzGerald PJ, Sergott RC, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal; optic-nerve; and cancer cells. N Engl J Med. 1989;321:1589-1594.
19. Yoon YH, Cho EH, Sohn J, Thirkill CE. An unusual type of cancer-associated retinopathy in a patient with ovarian cancer. Korean J Ophthalmol. 1999;13(1):43-48.
20. Rudge P. Optic neuritis as a complication of carcinoma of the breast. Proc R Soc Med. 1973;66:1106-1107.
21. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain. 1965;88(3):529-583.
22. Zeromski J, Wilkinson PC. Immunological aspects of carcinomatous neuropathy: some observations on the nature of the neuronal antigen. Pathol Eur. 1966;1(1):298-310.
23. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81:606-613.
24. Kornguth SE, Kalinke T, Grunwald GB, et al. Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome. Cancer Res. 1986;46:2588-2595.
25. Kornguth SE, Klein R, Appen R, Choate J. Occurrence of anti-retinal ganglion cell antibodies in patients with small cell carcinoma of the lung. Cancer. 1982;50:1289-1293.
26. Kornguth SE. Neuronal proteins and paraneoplastic syndromes. N Engl J Med. 1989;321:1607-1608.
27. Kornguth SE, Spear PE, Langer F. Reduction in numbers of large ganglion cells in cat retina following intravitreous injection of antibodies. Brain Res. 1982;245(1):35-45.
28. Klingele TG, Burde RM, Rappazzo JA, et al. Paraneoplastic retinopathy. J Clin Neuro-Ophthalmol. 1984;4:239-245.
29. Grunwald GB, Klein R, Simmonds MA, Kornguth SE. Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell lung carcinoma. Lancet. 1985;1:658-661.
30. Grunwald GB, Kornguth SE, Towfighi J, et al. Autoimmune basis for visual paraneoplastic syndrome in patients with small cell lung carcinoma. Retinal immune deposits and ablation of retinal ganglion cells. Cancer. 1987;60:780-786.
31. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL The cancer connection: an antigen immunologically related to the retinal CAR antigen is expressed in small cell carcinoma of the lung. In: Dernouchamps JP, editor. Proceedings of the Third International Symposium on Uveitis. Amsterdam/New York: Kugler Publications, 1993;133-135.
32. Polans AS, Witkowski D, Hayley TL, et al. Recoverin; a photoreceptor specific calcium-binding protein is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92:9176-9180.
33. Peek R, Verbraak F, Coevoet H, Kijlstra A. Muller cell-specific autoantibodies in a patientwith progressive lossof vision. Invest Ophthalmol Vis Sci. 1998;39:1976-1979.
34. Thirkill CE. Cancer associated retinopathy. The CAR syndrome. Neuro-Ophthalmology. 1994;14:297-323.
35. Thirkill CE. Cancer-induced retinal hypersensitivity. Br J Biomed Sci. 1996;53(3):227-234.
36. Thirkill CE. Lung cancer-induced blindness. Lung Cancer. 1996;14:253-264.
37. Honnorat J, Antoine JC. Value of detection of anti-nervous system autoantibodies in neurologic paraneoplastic syndromes. Rev Med Intern. 1994;15(2):124-133.
38. Sun JB. Autoreactive T and B cells in nervous system diseases. Acta Neurol Scand Suppl. 1993;142:1-56.
39. Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. 2000;8(2):93-100 (Review).
40. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38(2):283-291.
41. Spear PD, Jones KR, Zetlan SR, et al. Effects of antibodies to large ganglion cells on the cat's retinogeniculate pathway. J Neurophysiol. 1982;47(6):1174-1195.
42. Williams RW, Crabtree JW, Chalupa LM, et al. Selectivity of antibody-mediated destruction of axons in the cat's optic nerve. Brain Res. 1985;336(1):57-66.
43. Spear PD, Miller S, Vielhuber K, Kornguth SE. Visual field defects in cats with neonatal or adult immunological loss of retinal ganglion cells. Brain Res. 1986;368(1):154-157.
44. Crabtree JW, Spear PD, McCall MA, et al. Contributions of Y- and W-cell pathways to response properties of cat superior colliculus neurons: comparison of antibody- and deprivation-induced alterations. J Neurophysiol. 1986;56(4):1157-1173.
45. Crabtree JW, Spear PD, McCaII MA, et al. Dose-response analysis of effects of antibodies to large ganglion cells on the cat's retinogeniculate pathways. J Neurosci. 1986;6(5):1199-1210.
46. Kornguth S, Auerbach R, Grieves J, Kahan L. Immunological reactivity of monoclonal antibodies prepared against large ganglion cells from bovine retina. Neurosci Lett. 1981;27(2):151-157.
47. Richman DP, Agius MA. Acquired myasthenia gravis: immunopathology. Neurol Clin. 1994;12(2):273-284.
48. Adamus G, et al. Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:2626-2633.
49. Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. Prog Retin Res. 1986;5:57-109.
50. Strebelow M, Schlosser M, Ziegler B, et al. Karlsburg type I diabetes risk study of a general population: frequencies and interactions of the four major type I diabetes-associated autoantibodies studied in 9419 schoolchildren. Diabetologia. 1999;42(6):661-670.
51. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979;76:4350-4354.
52. Thirkill CE, Tait RC, Tyler NK, et al. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33(10):2768-2772.
53. Milam AH, Dacey DM, Dizhoor AM. Recoverin immunoreactivity in mammalian cone bipolar cells. Vis Neurosci. 1993;10(1):1-12.
54. Dizhoor AM, Ray S, Kumar S, et al. Recoverin: a calcium sensitive activator of retinal rod guanylate cyclase. Science. 1991;251:915-918.
55. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL, et al. Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen. Arch Ophthalmol. 1993;111(7):974-978.
56. Gregerson DS. Peripheral expression of ocular antigens in regulation and therapy of ocular autoimmunity. Int Rev Immunol. 2002;21(2-3):101-121 (Review).
57. Nussenblatt RB, et al. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol. 1990;144(5):1689-1695.
58. Nussenblatt RB, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997;123(5):583-592.
59. Nussenblatt RB, et al. Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann NY Acad Sci. 1996;778:325-337.
60. De Smet MD, Chan CC. Regulation of ocular inflammation: what experimental and human studies have taught us. Prog Retin Eye Res. 2001;20(6):761-797 (Review).
61. Polans AS, Buczylko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol. 1991;112:981-989.
62. Donoso LA, Rodrigues M, Vrabec TR, et al. IRBP: preparation and characterization of site-specific monoclonal antibodies. Curr Eye Res. 1990;9:357-362.
63. Donoso LA, Rorke LB, Shields JA, et al. S-antigen immunoreactivity in trilateral retinoblastoma. Am J Ophthalmol. 1987;103:57-62.
64. Adamus G, et al. Recoverin: a potent uveitogen for the induction of photoreceptor degeneration in Lewis rats. Exp Eye Res. 1994;59:447-456.
65. Igal Gery Chanaud NP, Anglade E. Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci. 1994;35(8):3342-3345.
66. Adamus G, Amundson D. Epitope recognition of recoverin in cancer associated retinopathy: evidence for calcium-dependent conformational epitopes. J Neurosci Res. 1996;45(6):863-872.
67. Polans AS, Burton MD, Haley TL, et al. Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(1):81-90.
68. Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol. 2002;514:109-124 (Review).
69. Thirkill CE, Keltner JL, Tyler NK, Roth AM. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol. 1993;111(7):931-937.
70. Rose NR, Milgrom F, Van Oss CJ. [E. Witebsky; 1901-1906]. Ann Inst Pasteur (Paris). 1970;119:555-556.
71. Witebsky E. Concept of autoimmune disease. Ann NY Acad Sci. 1966;135:443-450.
72. Adamus G. Antirecoverin antibodies and autoimmune retinopathy. Arch Ophthalmol. 2000;118(11):1577-1578.
73. Adamus G, et al. Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy. J Autoimmun. 2003;21(2):121-129.
74. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev. 2003;2(2):63-68.
75. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J. Neuroimmunol. 2002;132(1-2):72-82.
76. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev. 2003;2(2):63-68.
77. Adamus G, Machnicki M, Elerding H, et al. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11(5):523-533.
78. Chen W, Elias RV, Cao W, et al. Anti-recoverin antibodies cause the apoptotic death of mammalian photoreceptor cells in vitro. J Neurosci Res. 1999;57(5):706-718.
79. Drachman DB. How to recognize an antibody-mediated autoimmune disease: criteria. In: Waksman BH, editor. Immunologic mechanisms in neurologic and psychiatric disease. New York: Raven Press, 1990;183-186.
80. Meek B, Speijer D, deJong PT, et al. The ocular humoral immune response in health and disease. Prog Retin Eye Res. 2003;22(3):391-415 (Review).
81. Maeda A, Maeda T, Ohguro H, et al. Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice. Eur J Immunol. 2002;32(8):2300-2307.
82. Agius MA, Richman DP, Fairclough RH, et al. Three forms of immune myasthenia. Ann NY Acad Sci. 2003;998:453-456.
83. Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann NY Acad Sci. 2003;998:457-472.
84. Roitt IM, Hutchings PR, Dawe KI, et al. The forces driving autoimmune disease. J Autoimmun. 1992;5(Suppl A):11-26 (Review).
85. Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci. 2001;24:239-262 (Review).
86. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23(12):1800-1818 (Review).
87. Whitcup SM, Vistica BP, Milam AH, et al. Recoverin-associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol. 1998;126(2):230-237.
88. Hooks JJ, Detrick B, Percopo C, et al. Development and characterization of monoclonal antibodies directed against the retinal pigment epithelial cell. Invest Ophthalmol Vis Sci. 1989;30(10):2106-2113.
89. Faure JP, Mirshahi M, Dorey C, et al. Production and specificity of monoclonal antibodies to retinal S antigen. Curr Eye Res. 1984;3(6):867-872.
90. Bohle AR, et al. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. J Urol. 1996;155(6):1892-1896.
91. Matsubara S, et al. Expression of the phoreceptor protein recoverin; as a cancer-associated retinopathy autoantigen in human lung cancer cell lines. Br J Cancer. 1996;74(9):1419-1422.
92. Matsubara S, et al. Cancer-associated retinopathy syndrome: a case of small cell lung cancer expressing recoverin immunoreactivity. Lung Cancer. 1996;14(2-3):265-271.
93. Yamaji Y, Matsubara S, Yamadori I, et al. Characterization of a small-cell-lung-carcinoma cell line from a patient with cancer-associated retinopathy. Int J Cancer. 1996;65(5):671-676.
94. McGinnis JF, Lerious V Pazik J, Elliott RW. Chromosomal assignment of the recoverin gene and cancer-associated retinopathy. Mamm Genome. 1993;4(1):43-45.
95. McGinnis JF, Austin B, Klisak I, et al. Chromosomal assignment of the human gene for the cancer-associated retinopathy protein (recoverin) to chromosome 17p13.1. J Neurosci Res. 1995;40(2):165-168.
96. Miyagawa Y, Ohguro H, Odagiri H, et al. Aberrantly expressed recoverin is functionally associated with G-protein-coupled receptor kinases in cancer cell lines. Biochem Biophys Res Commun. 2003;300(3):669-673.
97. Voltz R, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340(23):1788-1795.
98. Gripp S, et al. Thymoma: prognostic factors and treatment outcomes. Cancer. 1998;83(8):1495-1503.
99. Moll JW, et al. Systemic and anti-neural autoantibodies in patients with paraneoplastic neurological disease. J Neurol. 1996;243(1):51-56.
100. Verschuuren JJ, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: studies on human tumor cell lines. J Neuroimmunol. 1997;79(2):202-210.
101. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp Quant Biol. 1989;54:1-13.
102. Thirkill CE. Experimental, cancer-induced retinopathy. Ocul Immunol Inflamm. 1997;5(1):55-65.
103. Ohkawa T, Kawashima H, Makino S, et al. Cancer-associated retinopathy in a patient with endometrial cancer. Am J Ophthalmol. 1996;122(5):740-742.
104. Adamus G, Chan CC. Experimental autoimmune uveitides: multiple antigens; diverse diseases. Int Rev Immunol. 2002;21(23):209-229.
105. Arai J, et al. Tubby-like protein 1 is one of the retinal autoantigens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1998;39(4):3326.
106. Eichen JG, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuro-Ophthalmol. 2001;21(3):168-172.
107. Ohguro H, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160-3167.
108. Ohguro H, Ogawa K, Nakagawa T. Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1999;40(1):82-89.
109. Peek R, Dukstra BG, Meek B, Kuijpers AM. Autoantibodies to photoreceptor membrane proteins and outer plexiform layer in patients with cancer-associated retinopathy. Clin Exp Immunol. 2002;128:498-503.
110. Gregerson DS, Fling SP, Wohlhueter RM. Characterization of immunologically active cyanogen bromide peptide fragments of bovine and human retinal S-antigen. Exp Eye Res. 1986;43:803-818.
111. Gregerson DS, Obritsch WF, Fling SR Identification of a uveitogenic cyanogen bromide peptide of bovine retinal S-antigen and preparation of a uveitogenic; peptide-specific T cell line. Eur J Immunol. 1987;17:405-411.
112. Gregerson DS, Knospe V, Donoso LA. Selection of antibody epitopes in an immunopathogenic neural autoantigen. J Neuroimmunol. 1989;24:191-206.
113. Dua HS, et al. Induction of experimental autoimmune uveitis by the retinal photoreceptor cell protein: phosducin. Curr Eye Res. 1992;11(Suppl):107-111.
114. Sergott RC, Brown MJ, Silberberg DH, Lisak RP. Antigalactocerebroside serum demyelinates optic nerve in vivo. J Neurol Sci. 1984;64(3):297-303.
115. Sergott RC, Brown MJ, Polenta RM, et al. Optic nerve demyelination induced by human serum: patients with multiple sclerosis or optic neuritis and normal subjects. Neurology. 1985;35:1438-1442.
116. Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve. 1986;9:523-530.
117. Buist MR, et al. Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab′)2: pharmacokinetics, tissue distribution, and tumor imaging. Int J Gynecol Cancer. 1992;2(1):23-34.
118. De Bree R, Roos JC, Verel I, et al. Radioimmunodiagnosisof lymph node metastases in head and neck cancer. Oral Dis. 2003;9(5):241-248.
119. Lee FT SF. Immuno-PET for tumor targeting. J Nucl Med. 2003;44(8):1282-1283.
120. Solomon B, et al. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. BioDrugs. 2003;17(5):339-354.
121. Esmaeli B, Koller C, Papadopoulos N, Romaguera J. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology. 2001;108(5):858-860.
122. Adler R, Curcio C, Hicks D, et al. Cell death in age-related macular degeneration. Mol Vis. 1999;5:31 (Review).
123. Kim DM, Koo SY, Jeon K, et al. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res. 2003;63(3):621-626.
124. Thirkill CE. Retinal pigment epithelial hypersensitivity, an association with vision loss: RPE hypersensitivity complicating paraneoplastic retinopathies. Ocul Immunol Inflamm. 2000;8(1):25-37.
125. Goldstein SM, Syed NA, Milam AH, et al. Cancer-associated retinopathy. Arch Ophthalmol. 1999;117(12):1641-1645.
126. Ling CP, Pavesio C. Paraneoplastic syndromes associated with visual loss. Curr Opin Ophthalmol. 2003;14(6):426-432.
127. Kattah JC, Suski ET, Killen JY, et al. Optic neuritis and systemic lymphoma. Am J Ophthalmol. 1980;89(3):431-436.
128. Kraus AM, O'Rourke J. Lymphomatous optic neuritis. Arch Ophthalmol. 1963;70:173-175.
129. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988;106:307-311.
130. Keltner JL, Thirkill CE, Yip PT Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuro-Ophthalmol. 2001;21(3):173-187 (Review).
131. Pfohler C, Haus A, Palmowski A, et al. Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol. 2003;149(1):74-78.
132. Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(1):91-100.
133. Singh AD, Milam AH, Shields CL, et al. Melanoma-associated retinopathy. Am J Ophthalmol. 1995;119(3):369-370.
134. Potter MJ, Thirkill CE, Dam OM, et al. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology. 1999;106(11):2121-2125.
135. Boeck K, Hofmann S, Klopfer M, et al. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol. 1997;137(3):457-460 (Review).
136. Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol. 1995;79(8):746-752.
137. Alexander KR, Fishman GA, Peachey NS, et al. On' response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci. 1992;33:477-483.
138. Osborne NN, Broyden NJ, Barnett NL, Morris NJ. Protein kinase C (alpha and beta) immunoreactivity in rabbit and rat retina: effect of phorbol esters and transmitter agonists on immunoreactivity and the translocation of the enzyme from cytosolic to membrane compartments. J Neurochem. 1991;57(2):594-604.
139. Lei B, Bush RA, Milam AH, Sieving PA. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci. 2000;41(1):262-266.
140. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase Il trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21(21):4016-4026.
141. Nussenblatt R, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21(3):283-293.
142. Potter MJ, Adamus G, Szabo SM, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol. 2002;134(1):128-130.
143. Kozhich AT, Kawano Y, Egwuagu CE, et al. A pathogenic autoimmune process targeted at a surrogate epitope. J Exp Med. 1994;180(1):133-140.
144. Thirkill CE, Keltner JL, Yip P, Wildberger H, Nickerson JM. Atypical antigen/antibody reaction in melanoma-associated retinopathy (MAR). Ocul Immunol Inflamm. 2001;9(4):277-278 (AUS Meeting abstract).
145. Keltner JL, Thirkill CE. The 22 kd antigen in optic nerve and retinal diseases. J Neuro-Ophthalmol. 1999;19(2):71-83.
146. Pfohler C, Thirkill C, Tilgen W. Rosette formation in melanoma: more frequent than suspected? Am J Dermatopathol. 2003;25(4):360-361.
147. To KW, Thirkill CE, Jakobiec FA, Lessell S, Berson EL Lymphoma-associated retinopathy. Ophthalmology. 2002;109(11):2149-2153.
148. Susac JO, Lawton-Smith J, O'Powell JO. Carcinomatous optic neuropathy. Am J Ophthalmol. 1973;76:672-679.
149. Anderson NE. Anti-neuronal autoantibodies and neurological paraneoplastic syndromes. Aust NZ J Med. 1989;19:379-387.
150. Waterson JA, Gilligan BS. Paraneoplastic optic neuritis and external ophthalmoplegia. Aust NZ J Med. 1986;16:703-704.
151. Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol. 1988;45:353-356.
152. Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and Optic neuritis': paraneoplastic effects of bronchial carcinoma. Neurology. 1984;34(6):788-791.
153. Yuki N, Yamada M, Tagawa Y, et al. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci. 1997;149(2):127-130.
154. Scaioli V, et al. Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case. J Neuro-Oncol. 1995;25(3):221-225.
155. Rubin P, et al. Ocular toxicity following high dose chemotherapy and autologous transplant. Bone Marrow Transplant. 1996;18(1):253-256.
156. Luiz JE, Lee A, Keltner JL, Thirkill CE, Lai C. Paraneoplastic optic neuropathy and autoantibody production in small cell carcinoma of the lung. J Neuro-Ophthalmol. 1998;18(3):178-181.
157. Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuro-Ophthalmol. 2001;21(3):164-167.
158. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38-50 (Review).
159. Murphy MA, Thirkill CE, Hart Jr WM. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuro-Ophthalmol. 1997;17(2):77-83.
160. Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a sub-population of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996;61:270-278.
161. De la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol. 1998;55(3):405-408.
162. Anderson NE, Cunningham JM, Posner JB. Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neurobiol. 1987;3:245-299.
163. Anderson NE. Paraneoplastic optic neuritis and external ophthalmoplegia. Australian and New Zealand Journal of Medicine. 1987;17:539.
164. Palmowski AM, et al. Bilateral multifocal chorioretinopathy in a woman with cutaneous malignant melanoma. Arch Ophthalmol. 2002;120(12):1756-1761.
165. Ross AH, Pleasure D, Sonnenfeld K, et al. Expression of melanoma-associated antigens by normal and neurofibroma Schwann cells. Cancer Res. 1986;46(11):5887-5892.
166. Seiter S, Ugurel S, Pfohler C, et al. Successful treatment of progressive vitiligo with high-dose intravenous methylprednisolone 'pulse' therapy. Dermatology. 1999;199(3):261-262.
167. Posner JB. Paraneoplastic syndromes. Curr Neurol. 1989;9:245-278.
168. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 1997;24(3):318-328 (Review).
169. Posner JB, Dalmau JO. Paraneoplastic syndromes affecting the central nervous system. Annu Rev Med. 1997;48:157-166 (Review).
170. Ohira A, et al. Glial-, neuronal- and photoreceptor-specific cell markers in rosettes of retinoblastoma and retinal dysplasia. Curr Eye Res. 1994;13(11):799-804.
171. Paone JP, Jeyasingham K. Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma. N Engl J Med. 1980;302:156.
172. Gogas J, et al. Granular cell tumor of the breast: a rare lesion resembling breast cancer. Eur J Gynaecol Oncol. 2002;23(4):333-334.
173. Pruneri G, et al. Follicular dendritic cell sarcoma of the breast. Virchows Arch. 2002;441(2):194-199.
174. Shibata H, et al. [A case of amelanotic melanoma of the nasal cavity]. Rinsho Byori. 2002;50(7):712-716 (in Japanese, abstract in English).
175. Shirley SE, et al. Clear cell carcinoma of the breast with immunohistochemical evidence of divergent differentiation. Ann Diagn Pathol. 2002;6(4):250-256.
176. Mitselou A, et al. Immunohistochemical study of the expression of S-100 protein; epithelial membrane antigen; cytokeratin and carcinoembryonic antigen in thyroid lesions. Anticancer Res. 2002;22(3):1777-1780.
177. Cesinaro AM, et al. 'Connective tissue nevus' and a serendipitous s-100 discovery. Am J Dermatopathol. 2003;25(1):86-87.
178. Molina R, et al. S-10O protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 2002;23(1):39-44.
179. Gonzalez-Martinez T, et al. S-100 proteins in the human peripheral nervous system. Microsc Res Tech. 2003;60(6):633-638.
180. Kim Y, et al. Acral lentiginous melanoma: an immunohistochemical study of 20 cases. Int J Dermatol. 2003;42(2):123-129.
181. Missotten GS, Tang NE, Korse CM, et al. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 2003;121(8):1117-1119.
182. Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25(2):197-204.
183. Glorieux I, Chabbert V, Rubie HBC, et al. Autoimmune hemolytic anemia associated with a mature ovarian teratoma. Arch Pediatr. 1998;5(1):41-44.
184. Doldi N, Taccagni GL, Bassan M, et al. Hashimoto's disease in a papillary carcinoma of the thyroid originating in a teratoma of the ovary (malignant struma ovarii). Gynecol Endocrinol. 1998;12(1):41-42.
185. Farrell DJ, Bloxham CA, Scott DJ. Hashimoto's disease in a benign cystic teratoma of the ovary. Histopathology. 1991;19(3):283-284.
186. Suhler EB, Chan CC, Caruso RC, et al. Presumed teratoma-associated paraneoplastic retinopathy. Arch Ophthalmol. 2003;121(1):133-137.
187. Shah A, Sadasivan B, Leng BM, HoJ. Ateratocarcinoma developing after gross total excision of a pineal teratoma in a patient with systemic lupus erythematosus. Neurol Res. 1995;17(3):229-232.
188. Labrune B, Habibi B, Courpotin C, et al. Auto-immune haemolytic anaemia and mediastinal dysembryoma in a 6-year-old child (author's transl). Nouv Presse Med. 1978;7(11):921-924.
189. Jerne NK. ldiotypic network and other preconceived ideas. Immunol Rev. 1984;79:5-24.
190. Singh VK, Yamaki K, Abe T, Shinohara T. Molecular mimicry between uveitopathogenic site of retinal S-antigen and Escherichia CoIi protein: induction of experimental autoimmune uveitis and lymphocyte cross-reaction. Cell Immunol. 1989;122(1):262-273.
191. Gregerson DS, Obritsch WF, Donoso L. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols. J Immunol. 1993;151(10):5751-5761.
192. Nussenblatt RB, et al. Strategies for the treatment of intraocular inflammatory disease. Transplant Proc. 1998;30(8):4124-4125 (Review).
193. Sulzer B, Van Hemmen JL, Behn U. Central immune system, the self and autoimmunity. Bull Math Biol. 1994;56(6):1009-1040.
194. Vassilev T, et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol. 1999;29(8):2436-2442.
195. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol. 2003;23(2):215-224 (Review).
196. Donofrio PD. lmmunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 2003;28(3):273-292 (Review).
197. De Kozak Y. Regulation of retinal autoimmunity via the idiotypic network. Curr Eye Res. 1990;9(Suppl):193-200.
198. Roitt IM, Cooke A. Manipulation of idiotype networks in autoimmunity. Ciba Found Symp. 1987;29:209-222 (Review).
199. Zanetti M, Rogers J, Katz DH. Perturbation of the autoimmune network. I. Immunization with anti-idiotypic antibodies prior to challenge with antigen induces quantitative variations in the autoantibody response. Autoimmunity. 1988;1(1):23-36.
200. Whitcup SM, DeBarge LR, Caspi RR, et al. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol. 1993;67(2):143-150.
201. Rao NA, Atalla L, Linker-Israeli M, et al. Suppression of experimental uveitis in rats by anti-I-A antibodies. Invest Ophthalmol Vis Sci. 1989;30(11):2348-2355.
202. De Kozak Y, Mirshahi M, Boucheix C, Faure JP. Inhibition of S-antigen-induced experimental autoimmune uveoretinitis by active immunization against anti-idiotypic antibody to an S-antigen epitope. Reg Immunol. 1992;4(3):168-174.
203. De Kozak Y, Stiemer RH, Mirshahi M, et al. Humoral immune response against the S-antigen/TNF alpha common epitope in rat EAU suppressed by the monoclonal antibody S2D2. Curr Eye Res. 1992;11(Suppl):119-127.
204. Caress JB, Cartwright MS, Donofrio PD, Peacock Jr JE. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60(11):1822-1824.
205. Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci. 2003;24(Suppl 4):S222-226 (Review).
206. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50(3):172-175.
207. Kodama S, Kuhtreiber W, Fujimura S, et al. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 2003;302(5648):1223-1227.
208. Larsson K, Lonnqvist B, Ringden O, et al. CMV retinitis after allogeneic bone marrow transplantation: a report of five cases. Transplant Infect Dis. 2002;4(2):75-79.
209. Adamus G, Sugden B, Shiraga S, et al. Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy. J Autoimmun. 2003;21(2):121-129.
210. Hauswirth WW, Beaufrere L. Ocular gene therapy: quovadis? Invest Ophthalmol Vis Sci. 2000;41(10):2821-2826.
211. Zhu C ZY, Pardridge WM. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci. 2002;43:3075-3080.
212. Zhang Y, Schlachetzki F, Li JY, et al. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis. 2003;9:465-472.
213. Hauswirth WW, McInnes RR. Retinal gene therapy 1998: summary of a workshop. Mol Vis. 1998;4:11.
214. Zhang L, Jayne DR, Oliveira DB. Anti-idiotype antibodies to anti-mitochondrial antibodies in the sera of patients with primary biliary cirrhosis. J Autoimmun. 1993;6(1):93-105.
215. Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140:1490-1495.
216. Caspi RR, Silver PB, Chan CC, et al. Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol. 1996;157(6):2668-2675.
217. Kaye FJ. Molecular biology of lung cancer. Lung Cancer. 2001;34(Suppl 2):S35-41 (Review).
218. Pinarbasi H, Silig Y, Cetinkaya O, et al. Strong association between the GSTM1-null genotype and lung cancer in a Turkish population. Cancer Genet Cytogenet. 2003;146(2):125-129.